[ad_1]
The vaccine was found to be 100% effective in preventing disease among trial participants in South Africa, where a mutated strain of the Corona virus known as (B1351) is spreading, despite the fact that the number number of participants was relatively small and reached 800.
While the new efficacy rate of 91.3% is lower than the 95% reported in a trial of 44,000 in November, a number of mutated strains of the coronavirus have spread around the world since then.
Albert Burla, chief executive of Pfizer, said the new findings, which include data from more than 12,000 people fully vaccinated at least six months ago, pave the way for a request for approval from US regulatory agencies.
The vaccine is approved by the United States Food and Drug Administration for emergency use.
Ugur Shaheen, CEO of Biontech, said the trial data “provides the first clinical results that prove that a vaccine can effectively protect against mutated strains currently in circulation, which is a critical factor in achieving immunity. of the herd and eliminate this pandemic “.
Experts fear that the new strains circulating in South Africa and Brazil may be resistant to current vaccines.
[ad_2]
Source link
